Recent

% | $
Quotes you view appear here for quick access.

Novo Nordisk A/S Message Board

  • tremulousbull tremulousbull Aug 14, 2012 1:45 PM Flag

    Interesting statement on Conference Call

    "And just to attach a couple of comments, it is highly unusual that you have an end of trial A1c that's actually below the ADA cut-off for defining overt type 2 diabetes." This was one of the results of a new phase 3a (the transcript of the CC said phase 2) trial on IDegLira. This interested me both as a Pharmacist and shareholder. Kudos NVO.

 
NVO
55.1698-0.5602(-1.01%)11:37 AMEDT